Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27248533 | 0.90 | HSD17B10 (0.50) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E | |
| SCHEMBL7089427 | 0.90 | TSHR (0.46) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E | |
| SCHEMBL27248599 | 0.87 | HSD17B10 (0.47) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E | |
| SCHEMBL6384036 | 0.86 | KDM4E (0.69) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E | |
| SCHEMBL3373962 | 0.86 | KDM4E (0.69) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E | |
| SCHEMBL1964219 | 0.86 | ALDH1A1 (0.53) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E | |
| SCHEMBL264389 | 0.86 | KDM4E (0.47) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E | |
| SCHEMBL299905 | 0.86 | ALDH1A1 (0.46) | HSD17B10ALDH1A1TSHRKDM4EDPP4 | |
| SCHEMBL7471868 | 0.85 | ALDH1A1 (0.63) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E | |
| Hydrochloric Acid SCHEMBL27984823 | 0.85 | KDM4E (0.46) | HSD17B10ALDH1A1TSHRCYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| CN-106146484-A | Quinazoline derivant is as RAF kinase modulator and their method and purposes | 埃姆比特生物科学公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| CN-102026985-B | Quinazoline derivatives as RAF kinase modulators and methods and uses thereof | 埃姆比特生物科学公司 | 2016-07-06 | — | — | CN | disclosed |
| US-9320739-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| CN-102026985-A | Quinazoline derivatives as RAF kinase modulators and methods and uses thereof | AMBIT BIOSCIENCES CORPORATON | 2011-04-20 | — | — | CN | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20030144308-A1 | Fructose 1,6-bisphosphatase inhibitors | BAUER PAUL H (US) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | HSD17B10 3559/4885ALDH1A1 2803/4885TSHR 1876/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HSD17B10 3473/4885ALDH1A1 2988/4885TSHR 897/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HSD17B10 3559/4885ALDH1A1 2803/4885TSHR 1876/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HSD17B10 3559/4885ALDH1A1 2803/4885TSHR 1876/4885 |
| US-20030144308-A1 | Fructose 1,6-bisphosphatase inhibitors | FBP1, HK1, G6PC1 | HSD17B10 835/4885ALDH1A1 1023/4885TSHR 4244/4885 |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HSD17B10 3559/4885ALDH1A1 2803/4885TSHR 1876/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HSD17B10 3559/4885ALDH1A1 2803/4885TSHR 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.